CoChat
Sign Up
Cited by 93Hepatitis C virus researchAnimal Virus Infections StudiesHIV/AIDS drug development and treatment

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Glecaprevir/Pibrentasvir: First Global Approval

Lamb, Yvette N.·2017·Drugs
DOI 10.1007/s40265-017-0817-y
Open this paper in CoChat — free account

Abstract

A fixed-dose combination tablet of the hepatitis C virus (HCV) NS3/4A protease inhibitor (PI) glecaprevir and the HCV NS5A inhibitor pibrentasvir [glecaprevir/pibrentasvir; MAVIRET™ (EU); MAVYRET™ (USA)] has been developed by AbbVie. Oral glecaprevir/pibrentasvir 300 mg/120 mg (three 100 mg/40 mg tablets) taken once daily has been approved by the EMA for the treatment of all major genotypes (genotypes 1-6) of chronic HCV infection in adults. It has also been approved by the US FDA for the treatment of adult patients with chronic HCV genotype 1-6 infection without cirrhosis and with compensated cirrhosis, and for the treatment of adult patients with HCV genotype 1 infection who previously have been treated with a regimen containing either an HCV NS5A inhibitor or an NS3/4A PI, but not both. This article summarizes the milestones in the development of glecaprevir/pibrentasvir leading to its first global approval in the EU and subsequent approval in the USA for chronic HCV infection.

Overview

Integrity signals

Registry

Crossref · 10.1007/s40265-017-0817-y

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 4

  1. Enanta Pharmaceuticals. Enanta announces Japanese Ministry of Health, Labour and Welfare grants priority review for AbbVies investigational HCV regimen of glecaprevir/ pibrentasvir (G/P) for the treatment of all major genotypes of chronic hepatitis C [media release]. 2017. http://www.enanta.com/ .
  2. Gane E, Lawitz EJ, Pugatch D, et al. EXPEDITION-IV: safety and efficacy of GLE/PIB in adults with renal impairment and chronic hepatitis C virus genotype 1–6 infection [abstract and poster no. LB-11]. Hepatology. 2016;64(6 Suppl.):1125A.
  3. Kowdley KV, Colombo M, Zadeikis N, et al. ENDURANCE-2: safety and efficacy of ABT-493/ABT-530 in hepatitis C virus genotype 2-infected patients without cirrhosis, a randomized, double-blind, placebo-controlled study [abstract and poster no. 73]. Hepatology. 2016;64(1 Suppl.):39A.
  4. Zeuzem S, Feld JJ, Wang S, et al. ENDURANCE-1: efficacy and safety of 8- versus 12-week treatment with ABT-493/ABT-530 in patients with chronic HCV genotype 1 infection [abstract and poster no. 253]. Hepatology. 2016;64(1 Suppl.):132A–3A.

Cited by

Sorted by citations

See all 93

Related

See all

Metadata

Authors
Lamb, Y. N.
Corresponding author
Lamb, Yvette N.
Venue
Drugs
Publisher
Springer Science and Business Media LLC
Published
2017-09-19
Volume
77
Issue
16
Pages
1797-1804
ISSN
  • 0012-6667 (ISSN-L)
  • 1179-1950
DOI
10.1007/s40265-017-0817-y
OpenAlex
W2754868188
Cited by
93
References
18
Citations by year
2026: 5 · 2025: 12 · 2024: 9 · 2023: 19 · 2022: 8 · 2021: 8 · 2020: 12 · 2019: 12 · 2018: 7 · 2017: 1
FWCI
1.26
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (unspecified)
Locations
  • Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Hepatitis C virus research
  • Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Keywords
glecaprevir/pibrentasvir, hepatitis C virus, chronic hepatitis C, NS3/4A protease inhibitors, NS5A inhibitors, fixed-dose combination, drug approval, HCV genotype 1-6, liver cirrhosis, AbbVie, drug development milestones
MeSH terms
Viral Proteases, Aminoisobutyric Acids, Antiviral Agents, Benzimidazoles, Cyclopropanes, Drug Combinations, Genotype, Humans, Leucine, Liver Cirrhosis, Proline, Pyrrolidines, Quinoxalines, RNA-Dependent RNA Polymerase, Serine Endopeptidases, Sulfonamides, United States, United States Food and Drug Administration, Hepacivirus, Drug Approval, Viral Nonstructural Proteins, Hepatitis C, Chronic, Nucleoside-Triphosphatase, Lactams, Macrocyclic, DEAD-box RNA Helicases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review